Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial

The double-blind, prospective, National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) showed a 50% reduction in the risk of breast cancer for tamoxifen versus placebo, yet many women at risk of breast cancer do not adhere to the 5-year course. This first report of the rich BCPT drug adherence data examines predictors of adherence. Between June, 1992 and September, 1997 13,338 women at high risk of breast cancer were randomly assigned to 20 mg/d tamoxifen versus placebo; we analyzed the 11,064 enrolled more than 3 years before trial unblinding. Primary endpoint was full drug adherence (100% of assigned pills per staff report, excluding protocol-required discontinuation) at 1 and 36 months; secondary was adequate adherence (76%–100%). Protocol-specified multivariable logistic regression tested lifestyle factors, controlling for demographic and medical predictors. About 13% were current smokers; 60% were overweight/obese; 46% had moderate/heavy physical activity; 21%, 66%, 13% drank 0, 0–1, 1+ drinks per day, respectively; 91% were adequately adherent at 1 month; and 79% were at 3 years. Alcohol use was associated with reduced full adherence at 1 month (P = 0.016; OR = 0.79 1+ vs. 0), as was college education (P <0.001; OR = 0.78 vs. high school); age (P < 0.001; OR = 1.4 age 60+) and per capita household annual income (P < 0.001; OR = 1.2 per $30,000) with increased adherence. Current smoking (P = 0.003; OR = 0.75), age (P = 0.024, OR = 1.1), college education (P = 0.037; OR = 1.4), tamoxifen assignment (P = 0.031; OR = 0.84), and breast cancer risk (P <.001; OR = 1.5 high vs. low) predicted adequate adherence at 36 months. There were no significant associations with obesity or physical activity. Alcohol use and smoking might indicate a need for greater adherence support. Cancer Prev Res; 4(9); 1393–400. ©2011 AACR.

[1]  M. Caleffi,et al.  Adherence to a Breast Cancer Screening Program and Its Predictors in Underserved Women in Southern Brazil , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[2]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[4]  J. Cuzick,et al.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Costantino,et al.  Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) , 2008 .

[6]  B. Bonanni,et al.  Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Winer,et al.  Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Cella,et al.  Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women , 2008, Breast Cancer Research and Treatment.

[9]  Matthew P Goetz,et al.  Early discontinuation of tamoxifen , 2007, Cancer.

[10]  R. Wredling,et al.  Adherence to drug treatment in association with how the patient perceives care and information on drugs. , 2007, Journal of clinical nursing.

[11]  M. Wallander,et al.  Factors associated with adherence to drug therapy: a population-based study , 2007, European Journal of Clinical Pharmacology.

[12]  D Gareth Evans,et al.  Predicting Compliance in a Breast Cancer Prevention Trial , 2006, The breast journal.

[13]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[14]  K. Kroenke,et al.  Factors Associated with Drug Adherence and Blood Pressure Control in Patients with Hypertension , 2006, Pharmacotherapy.

[15]  Timothy L. Lash,et al.  Adherence to tamoxifen over the five-year course , 2006, Breast Cancer Research and Treatment.

[16]  Gerardo Heiss,et al.  Long-term adherence with cardiovascular drug regimens. , 2006, American heart journal.

[17]  P. Doró,et al.  Utilization of oral antihyperglycemic drugs over a 7–year period (1998–2004) in a Hungarian population and adherence to drug therapy , 2005, European Journal of Clinical Pharmacology.

[18]  Neil Skolnik,et al.  Dietary Guidelines for Americans 2005 , 2005 .

[19]  M. Regan,et al.  Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Morrow,et al.  Managing Breast Cancer Risk , 2003 .

[21]  Jerry Avorn,et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. J. Cersosimo.  Tamoxifen for Prevention of Breast Cancer , 2003, The Annals of pharmacotherapy.

[23]  Rajiv Sarin,et al.  Tamoxifen non-compliance: does it matter? , 2002, The Lancet. Oncology.

[24]  Markku Heliövaara,et al.  Associations of body mass index and obesity with physical activity, food choices, alcohol intake, and smoking in the 1982-1997 FINRISK Studies. , 2002, The American journal of clinical nutrition.

[25]  J. Costantino,et al.  Methodological Issues in the Analysis of Quality of Life Data in Clinical Trials: Illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial , 2002 .

[26]  M. Mesbah,et al.  Statistical methods for quality of life studies : design, measurements and analysis , 2002 .

[27]  G. Alexopoulos,et al.  Stigma as a barrier to recovery: Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. , 2001, Psychiatric services.

[28]  J. Bryant,et al.  Duration of adjuvant tamoxifen therapy. , 2001, Journal of the National Cancer Institute. Monographs.

[29]  B. Bonanni,et al.  Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  T. Lash,et al.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[32]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[33]  J. Costantino,et al.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[35]  M. Pizzichetta,et al.  Tamoxifen as Adjuvant after Surgery for Breast Cancer and Tamoxifen or Placebo as Chemoprevention in Healthy Women: Different Compliance with Treatment , 1998, Tumori.

[36]  J. Eiser,et al.  Diet, smoking and exercise: interrelationships between adolescent health behaviours. , 1997, Child: care, health and development.

[37]  M. Clark,et al.  Depression, smoking, activity level, and health status: pretreatment predictors of attrition in obesity treatment. , 1996, Addictive behaviors.

[38]  W. Klein,et al.  Unrealistic Optimism: Present and Future , 1996 .

[39]  R. Jeffery,et al.  Smoking status, dietary intake, and physical activity in a sample of working adults. , 1996, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[40]  K. Matthews,et al.  Diet, alcohol, and physical activity as a function of smoking status in middle-aged women. , 1993, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[41]  R. Horwitz,et al.  Adherence to treatment and health outcomes. , 1993, Archives of internal medicine.

[42]  R. Klesges,et al.  Smoking status: effects on the dietary intake, physical activity, and body fat of adult men. , 1990, The American journal of clinical nutrition.

[43]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[44]  R. Cohen,et al.  Smoking and body mass in the natural history of physical activity: prospective evidence from the Alameda County Study, 1965-1974. , 1989, American journal of preventive medicine.

[45]  D. Ward,et al.  A study of factors associated with weight change in women who attempt smoking cessation. , 1989, Addictive behaviors.

[46]  S. Blair,et al.  Comparison of dietary and smoking habit changes in physical fitness improvers and nonimprovers. , 1984, Preventive medicine.

[47]  C. Fabian,et al.  Clinical pharmacology of tamoxifen in patients with breast cancer: Correlation with clinical data , 1981, Cancer.

[48]  L. Sternson,et al.  Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. , 1980, Cancer treatment reports.

[49]  H. Akaike.  A new look at the statistical model identification , 1974 .